Compare STC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STC | SRPT |
|---|---|---|
| Founded | 1893 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | 2000 |
| Metric | STC | SRPT |
|---|---|---|
| Price | $68.23 | $15.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 29 |
| Target Price | ★ $81.00 | $25.85 |
| AVG Volume (30 Days) | 215.8K | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | 0.55 | ★ 2.88 |
| Revenue | ★ $2,921,636,000.00 | $2,198,237,000.00 |
| Revenue This Year | $13.62 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $127.71 | ★ $5.39 |
| Revenue Growth | ★ 17.32 | 15.58 |
| 52 Week Low | $57.11 | $14.68 |
| 52 Week High | $78.61 | $25.32 |
| Indicator | STC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 36.12 |
| Support Level | $68.90 | N/A |
| Resistance Level | $72.91 | $18.16 |
| Average True Range (ATR) | 2.36 | 0.90 |
| MACD | -0.10 | -0.29 |
| Stochastic Oscillator | 67.74 | 8.92 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments: Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.